Skip to content

Investigating the effect of Gabapentin and chlorpheniramine mesotherapy on itching caused by hypertrophic burn scars

Comparison of the effect of oral Gabapentin with injectable chlorpheniramine in the form of mesotherapy on the control of itching caused by hypertrophic scars in burn patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230731058993N1
Enrollment
40
Registered
2024-08-10
Start date
2024-08-11
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Itching caused by hypertrophic scars after burns. Pruritus

Interventions

Intervention 1: Intervention group: subcutaneous injection of 1 ml of chlorpheniramine (mesotherapy) 10 mg along with 1 ml of lidocaine 2% in the healthy skin around the hypertrophic scar. Mesotherapy

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Being 18-65 years old Completing and signing the inform consent form Clinical diagnosis of hypertrophic burn scar At least two months have passed since the burn Burn less than 10% of TBSA Having pruritus Having history of second or third degree burns

Exclusion criteria

Exclusion criteria: Receiving a skin graft after a burn, patients suffering from wound infection due to burns, patients suffering from burns caused by chemicals or electric shock, suffering from perineal or facial burns, suffering from uncontrolled diabetes, inability to communicate and complete the questionnaire. having peripheral neuropathy or psoriatic skin diseases, history of epilepsy and taking anticonvulsant drugs, history of allergies and allergic reactions to used drugs, history of significant liver, kidney, brain, and cardiopulmonary disorders , pregnant women and lactating women, people who have cancer, people who are using anticoagulants

Design outcomes

Primary

MeasureTime frame
Pruritus. Timepoint: before the intervention and one, three, seven, fourteen, twenty-eight days later and two months after the intervention. Method of measurement: Visual analog scale.

Secondary

MeasureTime frame
Quality of life of patients. Timepoint: Before the intervention, fourteen and twenty-eight days later and two months after the intervention. Method of measurement: DLQI quality of life questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Setoodeh nia

Shiraz University of Medical Sciences

z.setoodeh74@gmail.com+98 71 3631 2925

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026